# HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies

Source: https://onco.cc/trials/nct06649708/  
OnCo record `nct06649708` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HX044 in advanced solid tumours, run by Hanx Biopharmaceuticals (Wuhan) Co., Ltd., now recruiting.

## Summary

HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT06649708 by Hanx Biopharmaceuticals (Wuhan) Co., Ltd., with 100 participants planned, started 2024-12-30 and due to reach its primary completion in 2025-10-31. Interventions recorded: HX044.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06649708
- Phase: 1/2
- Setting: A Phase I/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients with Advanced Solid Tumor Malignancies
- Sponsor: Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06649708: https://clinicaltrials.gov/study/NCT06649708

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06649708.json